Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy

Size: px
Start display at page:

Download "Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy"

Transcription

1 l FERTLTY AND STERLTY Vol. 62, 6, December 1994 Copyright e 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy Lyman B. Spaulding, M.D., Ph.D.* Department of Obstetrics and Gynecology, St. Joseph Hospital, and Colorado Permanent Medical Group, Denver, Colorado Objective: To determine the role of endometrial ablation and benign uterine pathology in menopausal women with refractory bleeding who were treated with continuous hormone replacement therapy (HRT). Design: Prospective. Setting: Health maintenance organization. Patients: One hundred seventy-one menopausal women with an average age of 55 were enrolled in an algorithm of continuous HRT, endometrial biopsy for bleeding with initial therapy, doubling of the progestin dose, hysteroscopy, and endometrial resection-ablation for continued refractory bleeding. ntervention: Endometrial biopsy, hormone manipulation, office hysteroscopy, and hysteroscopic resection -ablation. Main Outcome Measures: Refractory menopausal bleeding and benign uterine pathology. Results: One hundred sixty-two women completed the study. One hundred six (65.4%) remained free of bleeding at the end of the initial 3 months of hormone therapy. Fifty-six (34.6%) had one or more bleeding episodes and required office biopsy and an increase in dosage of progestin. Bleeding ceased in an additional 35 (87%) while 21 (13%) continued to bleed. Those patients underwent endometrial resection-ablation. Surgical specimen demonstrated endometrial polyps, submucous leiomyomas, and adenomyosis in 85.7% of the cases. All patients are now free of bleeding. Conclusion: Many women become amenorrheic on the initial dose of continuous HRT; however, if bleeding continues, most stop when the dosage of progestin is doubled. Benign uterine pathology may cause refractory bleeding in a small group of patients but may be eliminated with endometrial resection-ablation. Fertil Steril1994;62: Key Words: Hormone replacement therapy, menopausal bleeding, endometrial ablation The beneficial effects of estrogen (E) replacement therapy in postmenopausal women are now accepted widely. Relief of vasomotor symptoms, decreased risk of cardiovascular disease, prevention of osteoporosis, and relief of genitourinary symptoms are recognized benefits (1). One of the major drawbacks fore replacement is the need for the addition of a progestin in those women with an intact uterus. Received January 28, 1994; revised and accepted July 22, * Reprint requests: Lyman B. Spaulding, M.D., Ph.D., Department of Obstetrics and Gynecology, Colorado Permanente Medical Group, 8383 West Alameda Avenue, Lakewood, Colorado (FAX: ). Troublesome bleeding may be the factor that causes many women to discontinue therapy. Continuous administration of an E and progestin potentially offers elimination of all bleeding. Although bleeding with continuous hormone replacement therapy (HRT) has been reported in 30% to 40% of patients within the first 4 months of use, it usually has decreased to approximately 12.5% after 9 months of therapy (2). This refractory bleeding may provoke patient anxiety, dissatisfaction, and decreased compliance (3). Resectoscopic therapy for abnormal bleeding has been used for approximately 20 years. Endometrial polyps and submucous myomas have been described in a high percentage of women undergoing Vol. 62, 6, December 1994 Spaulding Endometrial ablation and HRT 1181

2 surgical therapy for refractory bleeding (4). The current study was begun to investigate and treat refractory bleeding in patients treated with continuous HRT. The uterine pathology, as well as the effect of endometrial resection and ablation, in this clinical setting were evaluated. MATERALS AND METHODS One hundred seventy-one consecutive patients with an average age of 55 years (range, 43 to 72) presented with menopausal symptoms or dissatisfaction with their current hormone regimen from a large health maintenance organization serving the Denver metropolitan area between June 1991 and May 1993 and were seen by the author in a single clinic. The diagnosis of menopause was made if the patients presented with nocturnal vasomotor symptoms and failed to have withdrawal bleeding for 2 consecutive months after a progestational challenge (medroxyprogesterone acetate A], 10 mg for 10 days) or a serum FSH and LH 40 miu/ml (conversion factor to S unit, 1.00). This process identified 78 patients ( 45.6%) of the cohort. The remaining 93 patients (54.4%) had never been on HRT, with a number of years of no menses, or had been tried on cyclic replacement and were desirous of no more monthly withdrawal bleeding. The average age of the study population was 55 years (range 43 to 72 years), gravidity 2.7 (range 0 to 8), parity 2.35 (range 0 to 6), and weight 67.9 kg (range 42.3 to kg). The ethnic breakdown was Anglo, 160 (93.5%); Hispanic, 9 (5.3%); and Asian, 2 (1.2%). All patients were begun on daily conjugated equine E (Premarin; Ayerst Laboratories, nc., Philadelphia, PA) mg and MPA (Provera; The Upjohn Company, Kalamazoo, M) 2.5 mg. Those with no bleeding after the first 3 months of therapy were requested to return in another 6 months, whereas those with bleeding underwent an endometrial biopsy and the dose of MPA was increased to 5.0 mg/d. After biopsy, patients were seen again in 3 months. Patients without bleeding were scheduled to be seen in another 6 months. Those who continued to bleed underwent office hysteroscopy (Olympus HYF Type P, Lake Success, NY) and were counseled individually and provided with written material outlining their options: stopping all hormone therapy, endometrial resection-ablation, or hysterectomy. All patients requested resection-ablation (Fig. 1). An outpatient ambulatory surgical center was used for all ablations. Anesthesia was induced using the general endotracheal technique. nitially, the patient's bladder was emptied by catheter and the cervical stroma infiltrated with 2 ml of a dilute vasopressin solution (20 U of vasopressin in 30 ml of saline) at the 2, 4, 8, and 10 o'clock position. The internal cervical os was dilated to 9 Hegar, and the continuous flow 22FR resectoscope (Olympus Hystero-resectoscope, Malpitas, CA) was used for all procedures. Chilled sorbitol solution (3.3%) with the CDS rrigation System (Zimmer Patient Care Division, Dover, OH) was used to distend the uterine cavity with intrauterine pressure no greater than 78 mm Hg. No endometrial preparation was used, and HRT was continued before and immediately after the surgical procedure. The ablation technique was accomplished in two steps. First, endometrial polyps, submucous myomas, and endometrial strips, from the entire cavity to a depth of 3 to 4 mm were resected using the loop electrode at loow of cutting current. These tissue samples were removed from the endometrial cavity using the Synevac Vacuum Curettage (Berkeley Medevices, nc., Berkeley, CA). Second, the entire uterine cavity was coagulated using the rollerbarrel electrode at loow of coagulation current. The electrical generator used was the Force 2 (Valley Lab, n., Boulder, CO). All tissue specimens were submitted to pathology. Patients were observed in the outpatient facility and discharged to home within 3 hours. All patients in this study were followed for at least 9 months, and the longest follow-up was 32 months. RESULTS One hundred seventy-one menopausal patients were entered into the study. Nine patients did not complete the study. Four women stopped hormone therapy because of unacceptable bleeding. One stopped because of a newly diagnosed breast cancer, 1 because of emotional problems, 1 lost her health insurance, and 2 patients were lost to follow-up. At the end of the initial 3 month phase 106 (65.4%) women reported no bleeding and experienced no further bleeding during the study. Fifty-six women (34.6%) reported bleeding and underwent office endometrial biopsy. The dosage of progestational agent (MP A) was then increased to 5 mg. All biopsies were benign (Table 1). The single patient with insufficient tissue underwent a second office biopsy plus ultrasound imaging of the endometrial stripe. The second biopsy was reported also as insufficient tissue and the endometrial strip was 3 mm in 1182 Spaulding Endometrial ablation and HRT Fertility and Sterility

3 Diagnosis of menopause (n = 171) Continuous hormone replacement therapy* Discontinued patients (n = 9) Three months (n = 162) Bleeding (n =56) Office biopsy (nonmalignant) + Progestational agentt Three months No bleeding (n = 106) Followup at six months Figure 1 Management protocol for continuous HRT. Bleeding (n = 21) Office hysteroscopy Endometrial ablation No bleeding (n = 35) Followup at six months thickness. These 56 patients were seen again after a second 3-month interval. After increasing MPA to 5.0 mg, 35 additional patients became amenorrheic (87%) but 21 (12.9%) continued to bleed. Endometrial histology from these 21 women were similar to those previously sampled. (Table 2). Endometrial polyps, submucous leiomyomas, and normal cavities were observed in this subset of patients at office hysteroscopy. One patient was noted to have polyps and leiomyomas. All patients with refractory bleeding underwent endometrial resection-ablation with the exception of 1 patient. Because of equipment malfunction, this patient only had resection performed. The pathological specimens were benign with endometrial polyps (47.6%) and submucous Table 1 Endometrial Histology After the First 3 Months of Treatment* Diagnosis nactive endometrium Atrophic nsufficient tissue * n = (76.8)t 6 (10.7) 6 (10.7) 1 (1.8) leiomyomata (33.3%) predominating (Table 3). A number of specimens contained more than a single pathological entity. Sorbitol (3.3%) uptake averaged 337 ml (range, 0 to 1,300 ml). Blood loss was minimal, and there were no complications in this series. None of these patients are bleeding at this time. DSCUSSON Approximately 36 million American women could spend one third of their lives in a hypoestrogenic state. With modern HRT, this condition can be avoided. Estrogen replacement can be accomplished by pills, patches, subdermal capsules and M injections. However, endometrial hyperplasia and uterine cancer have been associated with prolonged use of unopposed E (5). By decreasing nuclear E receptors (6), blocking DNA synthesis (7), and decreasing cell multiplication (8), progestins offer a protective effect when combined with E. Replacement therapy has been prescribed to mimic the natural monthly withdrawal cycle, but after 40 years of monthly menses, most menopausal women would like to eliminate these bleeding episodes. Daily ingestion of an E and a progestin (con- Vol. 62, 6, December 1994 Spaulding Endometrial ablation and HRT 1183

4 Table 2 Patient Characteristics With Refractory Bleeding* Endometrial histology Office hysteroscopy nactive endometrium Atrophic endometrium nsufficient tissue 16 (76.2)t Endometrial polyps Submucous leiomyoma Normal cavity 12 (54.5)t 7 (31.8) 3 (13.6) * n = 21. tinuous HRT) has the potential to eliminate all bleeding. Although 90% of women on cyclic HRT experience withdrawal bleeding (9), only 30% to 40% have bleeding on daily therapy. This incidence of bleeding has decreased to 12.5% by 9 months (2) and approximately 10% by 1 year. Perimenopausal status (10), dosage of E (11), patient weight (12), progestational dose (13), and progestational type (14) have all been reported to influence bleeding with daily combined therapy. Any bleeding while on replacement therapy limits compliance. n one study 57% of women stopped taking cyclic therapy because of withdrawal bleeding. n hysterectomized women, only 21% discontinued E therapy (15). Bleeding appears to be the number one reason for discontinuing HRT. Because of this common problem, a protocol of biopsy, hormone manipulation, office hysteroscopy, and endometrial ablation was initiated (Fig. 1). Medroxyprogesterone acetate was increased to 5.0 mg/d after 3 months of irregular bleeding. Although Weinstein et al.(16) noted no difference in bleeding patterns between 2.5 and 5.0 mg, many women in our patient population stopped bleeding on the 5.0-mg dose, yielding an 87% level of amenorrhea at 6 months of therapy. Weinstein et al. (16) also demonstrated that the higher dose of MP A did not cause deterioration of lipid profile. No hyperplasia or overt cancers were noted on office biopsy Table 3 Histologic Features at Endometrial Resection-Ablation* Diagnosis Endometrial polyps Leiomyomata nactive endometrium Adenomyosis Cystic atrophy * n = (47.6) 7 (33.3) 3 (14.3) or surgical specimens. This finding is consistent with other reports (17) and is thought to be due to the antiestrogen effect of the progestins. Recent reports that have included a few postmenopausal women, describing abnormal bleeding due to benign uterine pathology are consistent with this study. n Loffer's (4) report on large symptomatic intrauterine growths, he included 6 postmenopausal women who were noted to have polyps ( 4/ 16) and leiomyoma (2/16) as the cause of their bleeding. Brooks and Serdan (18) included 13 postmenopausal women in their report of 26 women bleeding after the age of 50. Overall, 58% of their patients demonstrated adenomyosis, whereas only 35% and 4% were found to have leiomyoma and polyps, respectively. The series by tzkowic (19) contained 5 postmenopausal patients in his report of 37 women with bleeding because of submucous leiomyomas. These women accounted for 13.5% of his population. Similarly, lndman (20) described 7 postmenopausal women in his 51 patients treated for menorrhagia for a similar rate of 13.7%. The results in this portion ofthe study of 21 menopausal women more closely match Loffer's work with our finding of adenomyosis in only one patient. Although benign uterine pathology causing clinical problems is diminished in frequency at the menopause, there appears to be a small group of patients who when challenged by HRT respond with unacceptable uterine bleeding. Whether this bleeding is due to hormonal stimulation of polyps and submucous leiomyomas that were present before HRT or the induction of new growths remains to be determined. Even though this study was not randomized and lacked a control group, the protocol described may select for those postmenopausal patients who can best benefit from removal of benign uterine pathology. Conclusions to be drawn from this study include the following: [l]many women will cease or continue to have no menses on the initial dose of continuous hormone therapy (65.4%); [2]increasing 1184 Spaulding Endometrial ablation and HRT Fertility and Sterility

5 - the dose of progestin may enhance levels of amenorrhea (87%); [3]benign uterine pathology may cause refractory bleeding in a small group of patients (13%); and [4]endometrial resection-ablation may correct the bleeding, thus encouraging them to maintain compliance with HRT. REFERENCES 1. American College of Obstetricians and Gynecologists, Hormone replacement therapy. ACOG Technical Bulletin no Washington, DC: American College of Obstetricians and Gynecologists, Prough SG, Aksel S, Wiebe H, Shepherd, J. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987;157: Derman SG, Rehnstrom J, Neuwirth, RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol1991;77: Loffer FD. Removal of large symptomatic intrauterine growth by the hysteroscopic resectoscope. Obstet Gynecol 1990;76: World Health Organization. Research on the menopause. World Health Organization Technical Report Series 670. Geneva: WHO, Hsveh AJW, Peck EJ, Clark JH. Control of uterine estrogen receptor levels by progesterone. Endocrinology 1976;98: Whitehead Ml, Townsend PT, Pryse-Davies J, Ryder JA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Eng! J Med 1981;305: Gerschenson LE, Berliner J, Yang JJ. Diethylstilbestrol and progesterone regulation of cultured rabbit endometrial cell growth. Cancer Res 1974;34: Whitehead Ml, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75:59S-76S. 10. Mattson L, Samsioe G. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. Acta Obstet Gynecol Scand Suppl 1985;130: Magos AL, Brincat M, Studd JWW, WardLE, Schlesinger P, O'Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy on postmenopausal women. Obstet Gynecol 1985;65: Sporrong T, Samsioe G, Larsen S, Mattson LA. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. Maturitas 1989;11: Yancey MK, Hannan CJ Jr, Plymate SR, Stone K, Friedl KE, Wright JR. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990;54: Jensen J, Riis BJ, Strom V, Christiansen C. Continuous estrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987;94: Hemminki F, Brambilla DJ, MacKinlay SM, Posner JG. Use of estrogens among middle-aged massachusetts women. DCP 1991;25: Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low dose regimen of estrogen progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990;162: Bewtra C, Kable WT, Gallagher JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 1988;33: Brooks PG, Serden SP. Endometrial ablation in women with abnormal uterine bleeding aged fifty and over. J Reprod Med 1992;37: tzkowic D. Submucous fibroids: clinical profile and hysteroscopic management. Aust NZ J Obstet Gynecol 1993; 33: ndman PD. Hysteroscopic treatment of menorrhagia associated with uterine leiomyomas. Obstet Gynecol 1993;81: Vol. 62, 6, December 1994 Spaulding Endometrial ablation and HRT 1185

Frequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.

Frequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc. Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses

More information

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes* FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term

More information

Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation

Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,

More information

Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages

Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the

More information

5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist

5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist Abnormal Uterine FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology May 5, 2010 About

More information

Role of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation

Role of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhari KR et al. Int J Reprod Contracept Obstet Gynecol. 2014 Sep;3(3):666-670 www.ijrcog.org pissn 2320-1770 eissn 2320-1789

More information

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists

More information

Investigation of abnormal uterine bleeding in perimenopausal women by hysteroscopy and endometrial biopsy

Investigation of abnormal uterine bleeding in perimenopausal women by hysteroscopy and endometrial biopsy Gynecol Surg (2005) 2: 51 55 DOI 10.1007/s10397-004-0076-2 CURRENT REFERENCES I. Stamatellos Æ P. Stamatopoulos Æ D. Rousso E. Asimakopoulos Æ C. Stamatopoulos Æ I. Bontis Investigation of abnormal uterine

More information

Hysterectomy : A Clinicopathologic Correlation

Hysterectomy : A Clinicopathologic Correlation Bahrain Medical Bulletin, Vol. 28, No.2, June 2006 Hysterectomy : A Clinicopathologic Correlation Layla S Abdullah, FRCPC* Objective : To study the most common pathologies identified in hysterectomy specimens

More information

Conflicts 10/5/2016. Abnormal Uterine Bleeding. Objectives Review diagnosis and updated nomenclature. Management options for acute and chronic AUB.

Conflicts 10/5/2016. Abnormal Uterine Bleeding. Objectives Review diagnosis and updated nomenclature. Management options for acute and chronic AUB. Abnormal Uterine Bleeding Barbara L. Keller, MD JD Naval Hospital Oak Harbor OB/GYN Physician Conflicts I have no conflicts or financial interests to disclose. Objectives Review diagnosis and updated nomenclature.

More information

AUB. Postmenopausal. Approximately 1 of every 8 postmenopausal. Rule out endometrial cancer first OBG COVER ARTICLE

AUB. Postmenopausal. Approximately 1 of every 8 postmenopausal. Rule out endometrial cancer first OBG COVER ARTICLE OBG MANAGEMENT COVER ARTICLE Postmenopausal AUB Rule out endometrial cancer first When a postmenopausal woman presents with abnormal uterine bleeding, endometrial cancer is the biggest concern. But a host

More information

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis

More information

Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women

Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women Sangchai Preutthipan, M.D., and Yongyoth Herabutya, F.R.C.O.G. Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi

More information

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW. PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Excessive menstrual blood loss

Excessive menstrual blood loss Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia

More information

Subject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy

Subject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Abnormal uterine bleeding, see also Adenomyosis, Endometrial cancer, Menorrhagia dilatation and curettage 21, 22, 25 hysteroscopy of premenopausal women anesthesia

More information

PALM-COEIN: Your AUB Counseling Guide

PALM-COEIN: Your AUB Counseling Guide PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural

More information

Non-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml

More information

Menstrual Disorders & Ambulatory Gynaecology

Menstrual Disorders & Ambulatory Gynaecology Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible

More information

DIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE

DIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE Original Article DIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE Abstract : 1 2 3 4 Neetha Nandan, Lakshmi Manjeera, Supriya Rai & Mangala Gowri

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

Transvaginal ultrasonography and hysteroscopy in postmenopausal bleeding a prospective study

Transvaginal ultrasonography and hysteroscopy in postmenopausal bleeding a prospective study Acta Obstet Gynecol Scand 2001; 80: 856 862 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE

More information

Said Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Said Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt ARC Journal of Gynecology and Obstetrics Volume 1, Issue 2, 2016, PP 7-12 ISSN No. (Online) 2456-0561 http://dx.doi.org/10.20431/2456-0561.0102003 www.arcjournals.org Efficacy and Acceptability of two

More information

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics

More information

Over the past year, a few gems have been

Over the past year, a few gems have been UPDATE Abnormal uterine bleeding Howard T. Sharp, MD Dr. Sharp is Professor and Vice Chair for Clinical and Quality Activities, Department of Obstetrics and Gynecology, University of Utah Health Sciences

More information

Intrauterine and subdermal progestin administration postmenopausal hormone replacement therapy

Intrauterine and subdermal progestin administration postmenopausal hormone replacement therapy FERTILITY AND STERILITY Vol. 63, No.2, February 1995 Copyright c 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Intrauterine and subdermal progestin administration

More information

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes

More information

of AUB DISCLOSURES 10/29/2018

of AUB DISCLOSURES 10/29/2018 of AUB DR. DEBRA GIERUT MD DEPARTMENT OF OBSTETRICS AND GYNECOLOGY KAISER PERMANENTE, ORANGE COUNTY DISCLOSURES I have no financial disclosures Lisa Samerdyke, the Director of National Accounts for Hologic

More information

Abnormal uterine bleeding:

Abnormal uterine bleeding: Primary Care Women s Health Forum 16th June 2010 Abnormal uterine bleeding: The University Of Birmingham T Justin Clark MD (Hons), MRCOG Consultant Obstetrician and Gynaecologist Birmingham Women s Hospital

More information

Gynecologic Decision Making Based on Sonographic Findings

Gynecologic Decision Making Based on Sonographic Findings Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco

More information

5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe

5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe 5 Mousa Al-Abbadi Ola Al-juneidi & Obada Zalat Ahmad Al-Tarefe Abnormal Uterine Bleeding (AUB) AUB is a very common scenario or symptom where women complain of menorrhagia (heavy and/or for long periods),

More information

Management of Abnormal Uterine Bleeding. Julie Strickland MD, MPH University of Missouri Kansas City Department of Obstetrics and Gynecology

Management of Abnormal Uterine Bleeding. Julie Strickland MD, MPH University of Missouri Kansas City Department of Obstetrics and Gynecology Management of Abnormal Uterine Bleeding Julie Strickland MD, MPH University of Missouri Kansas City Department of Obstetrics and Gynecology AUB Abnormal uterine bleeding (AUB): fairly broad term referring

More information

Managing Menstrual Disorders

Managing Menstrual Disorders Managing Menstrual Disorders David G. Weismiller, MD, ScM, FAAFP Professor Department of Family Medicine The Brody School of Medicine at East Carolina University Greenville, North Carolina Learning Objectives

More information

Comparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Abnormal Uterine Bleeding

Comparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Abnormal Uterine Bleeding JSLS Comparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Uterine Bleeding Lubna Pal, MD, L. Lapensee, MD, T.L. Toth, MD, K.B. Isaacson, MD ABSTRACT INTRODUCTION

More information

ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA. Study Patients

ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA. Study Patients ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA HUGH O CONNOR, M.R.C.O.G., AND ADAM MAGOS, M.D. ABSTRACT Background Endometrial resection is

More information

Hysteroscopy - current trends and challenges

Hysteroscopy - current trends and challenges J Obstet Gynecol India Vol. 58, No. 1 : January/February 2008 pg 57-62 Original Article Hysteroscopy - current trends and challenges Gour A, Zawiejska A, Mettler L Department of Obstetrics and Gynaecology,

More information

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,

More information

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation

More information

Gayatrri Anipindi *, Vani I. Original Research Article. Abstract

Gayatrri Anipindi *, Vani I. Original Research Article. Abstract Original Research Article Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: A safe and effective option for all PALM COEIN variants Gayatrri Anipindi *, Vani

More information

Out Patient Hysteroscopy Unit GUIDELINES

Out Patient Hysteroscopy Unit GUIDELINES Out Patient Hysteroscopy Unit GUIDELINES 1 AIMS The aim of the menstrual assessment clinic [MAC] (incorporating outpatient hysteroscopy) at Queen Charlotte s and Chelsea Hospital will be to provide a one-stop

More information

REPRODUCTIVE ENDOCRINOLOGY

REPRODUCTIVE ENDOCRINOLOGY REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 76, NO. 2, AUGUST 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in

More information

STOP/START. On the Web. 12 intraoperative videos from Dr. Garcia, at

STOP/START. On the Web. 12 intraoperative videos from Dr. Garcia, at Diagnostic hysteroscopy spies polyp previously missed on transvaginal ultrasound and dilation and curettage. STOP performing dilation and curettage for the evaluation of abnormal uterine bleeding START

More information

Dysfunctional Uterine Bleeding

Dysfunctional Uterine Bleeding Long term effects of PCOS Dysfunctional Uterine Bleeding Dr. Arulmozhi Ramarajan Church of South India Hospital, Bangalore Abnormal uterine bleeding Affects health-related QOL Causes social embarrasment

More information

Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding

Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta

More information

Perimenopausal Age Group (45-55yrs): For Early Detection And Treatment.

Perimenopausal Age Group (45-55yrs): For Early Detection And Treatment. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 9 Ver. 4 (September. 2018), PP 73-77 www.iosrjournals.org Perimenopausal Age Group (45-55yrs):

More information

ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017

ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 Philippe Laberge MD FRCSC ACGE Professor Obstetrics and Gynecology Laval University Quebec, Canada Disclosures I have used products or done clinical

More information

Medical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health

Medical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health Medical Management of Fibroids Esmya Dr Paula Briggs Consultant in Sexual and Reproductive Health Treatment options for Uterine Fibroids ESMYA Selective Uterine Artery Embolisation Fibroid ablation (hysteroscopic

More information

Long-term Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique

Long-term Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique Longterm Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique L. Mettler, Prof Dr Med SCIENTIFIC PAPER ABSTRACT Background and Objectives: Evaluation

More information

Endometrial line thickness in different conditions.

Endometrial line thickness in different conditions. Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens

More information

Summary CHAPTER 1. Introduction

Summary CHAPTER 1. Introduction Summary This thesis aims to evaluate the diagnostic work-up in postmenopausal women presenting with abnormal vaginal bleeding. The Society of Dutch Obstetrics and Gynaecology composed a guideline, which

More information

JSLS. Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates. Herbert A. Goldfarb, MD ABSTRACT INTRODUCTION

JSLS. Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates. Herbert A. Goldfarb, MD ABSTRACT INTRODUCTION JSLS Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates Herbert A. Goldfarb, MD ABSTRACT Background: This study compares results of endometrial ablation alone

More information

Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women

Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women 60 CANCER CYTOPATHOLOGY Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women Edi Brogi, M.D., Ph.D. Rosemary Tambouret, M.D. Debra A. Bell, M.D. Department

More information

Comparison of Sonography, Sonohysterography, and Hysteroscopy for Evaluation of Abnormal Uterine Bleeding

Comparison of Sonography, Sonohysterography, and Hysteroscopy for Evaluation of Abnormal Uterine Bleeding Comparison of Sonography, Sonohysterography, and Hysteroscopy for Evaluation of Abnormal Uterine Bleeding Mo H. Saidi, MD, R. Kent Sadler, MD, Vernon D. Theis, MD, Bruce D. Akright, MD, Scott A. Farhart,

More information

Appendix: Reference Table of HT Brand Names

Appendix: Reference Table of HT Brand Names Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug

More information

HYSTEROSCOPIC SURGERY AT THE AGA KHAN HOSPITAL, NAIROBI. R.B. PARKAR and N. G. THAGANA ABSTRACT

HYSTEROSCOPIC SURGERY AT THE AGA KHAN HOSPITAL, NAIROBI. R.B. PARKAR and N. G. THAGANA ABSTRACT 336 EAST AFRICAN MEDICAL JOURNAL July 2004 East African Medical Journal Vol. 81 No. 7 July 2004 HYSTEROSCOPIC SURGERY AT THE AGA KHAN HOSPITAL, NAIROBI R. B., Parkar, MBBS, MMed, Consultant Obstetrician,

More information

Aulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked

Aulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked Authors : Aulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked Faculty of Medicine University of Riau Pekanbaru, Riau 2009 Files of DrsMed FK UR (http://www.files-of-drsmed.tk 0 INTTRODUCTION

More information

Elaina Sexton, MD, MSc Obstetrics and Gynecology St. Vincent s Hospital. Objectives

Elaina Sexton, MD, MSc Obstetrics and Gynecology St. Vincent s Hospital. Objectives Elaina Sexton, MD, MSc Obstetrics and Gynecology St. Vincent s Hospital Objectives Definition of normal menstrual cycle and abnormal uterine bleeding (AUB) Evaluation of AUB Medical options for AUB Surgical

More information

GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY

GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY Training: Part 1 Anatomy and Physiology Female Anatomy Normal Uterus Female Anatomy Normal Uterus Female Anatomy Uterine Positions Abnormal Uterus Retroflexed Normal

More information

Abnormal Uterine Bleeding. Richard Dover Specialist gynaecologist

Abnormal Uterine Bleeding. Richard Dover Specialist gynaecologist Abnormal Uterine Bleeding Richard Dover Specialist gynaecologist A pragmatic guide. Wide topic range What s not coming up Precocious puberty Menorrhagia well maybe just a little Topics Adolescents IMB

More information

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS (339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting

More information

Management of Endometrial Hyperplasia

Management of Endometrial Hyperplasia Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New

More information

ASHERMAN S SYNDROME FOLLOWING THERMAL ABLATION OF THE ENDOMETRIUM Sheila K. Pillai 1, Bhuvana S 2, Jaya Vijayaraghavan 3

ASHERMAN S SYNDROME FOLLOWING THERMAL ABLATION OF THE ENDOMETRIUM Sheila K. Pillai 1, Bhuvana S 2, Jaya Vijayaraghavan 3 ASHERMAN S SYNDROME FOLLOWING THERMAL ABLATION OF THE ENDOMETRIUM Sheila K. Pillai 1, Bhuvana S 2, Jaya Vijayaraghavan 3 HOW TO CITE THIS ARTICLE: Sheila K. Pillai, Bhuvana S, Jaya Vijayaraghavan. Asherman

More information

INTRODUCTION. British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp

INTRODUCTION. British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp. 329-334 The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women

More information

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome*t

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome*t FERTILITY AND STERILITY Vol. 62, No. 5, November 1994 Copyright 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Depot leuprolide acetate with estrogen and progestin add-back

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

PRM Associated Endometrial Change Introduction & Illustrations 12-Feb-2012

PRM Associated Endometrial Change Introduction & Illustrations 12-Feb-2012 Introductory Remarks: These images are from clinical trial endometrial samples collected by catheter biopsy. They are presented with a low power section view with selected higher power images to show detailed

More information

Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding

Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Vol. 65, No, 6, June 1996 Printed on acid-free paper in U. S. A Hysteroscopy in women with abnormal uterine bleeding on

More information

International Journal of Medical and Health Sciences

International Journal of Medical and Health Sciences International Journal of Medical and Health Sciences Journal Home Page: http://www.ijmhrs.net ISSN:2277-4505 Original article Comparison Of Imaging Modalities In Abnormal Uterine Bleeding : Correlation

More information

Orals,Transdermals, and Other Estrogens in the Perimenopause

Orals,Transdermals, and Other Estrogens in the Perimenopause Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter

More information

COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006

COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006 COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006 CONSENSUS STATEMENT ON THE MANAGEMENT AND EVALUATION OF MENORRHAGIA (INCLUDING MANAGEMENT OF FIBROIDS) Introduction Menorrhagia is defined as

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

OVERVIEW OF MENOPAUSE

OVERVIEW OF MENOPAUSE OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause

More information

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer Original Article Obstet Gynecol Sci 2018;61(5):615-620 https://doi.org/10.5468/ogs.2018.61.5.615 pissn 2287-8572 eissn 2287-8580 The effect of tamoxifen therapy on the endometrium and ovarian cyst formation

More information

Hormone therapy for menopausal vasomotor symptoms

Hormone therapy for menopausal vasomotor symptoms Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert

More information

Intrauterine delivery of progestogen in the peri- and postmenopausal women. Outline of the presentation. Levonorgestrel releasing IUS - Mirena

Intrauterine delivery of progestogen in the peri- and postmenopausal women. Outline of the presentation. Levonorgestrel releasing IUS - Mirena QuickTime ja Valokuva - JPEG pakkauksen purkuohjelma tarvitaan elokuvan katselemiseen. Intrauterine delivery of progestogen in the peri- and postmenopausal women ESHRE Campus meeting 6.-7.10.2008 Oskari

More information

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines

More information

Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre

Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4

More information

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 Introduction Bleeding with contraception may lead to discontinuation and possible unintended pregnancy What

More information

Citation for published version (APA): Timmermans, A. (2009). Postmenopausal bleeding : studies on the diagnostic work-up

Citation for published version (APA): Timmermans, A. (2009). Postmenopausal bleeding : studies on the diagnostic work-up UvA-DARE (Digital Academic Repository) Postmenopausal bleeding : studies on the diagnostic work-up Timmermans, A. Link to publication Citation for published version (APA): Timmermans, A. (2009). Postmenopausal

More information

Is Outpatient Hysteroscopy the New Gold Standard?

Is Outpatient Hysteroscopy the New Gold Standard? Is Outpatient Hysteroscopy the New Gold Standard? McIlwaine K, Readman E, Ma T, Manwaring J, Ellett L, Hicks L, Porter J, Cameron M, Maher P. Mercy Hospital for Women, Melbourne, Australia Background Abnormal

More information

First-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional bleeding

First-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional bleeding Gynecol Surg (2015) 12:291 297 DOI 10.1007/s10397-015-0902-8 ORIGINAL ARTICLE First-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional

More information

Comparative Study of Transvaginal Sonography and Hysteroscopy for the Detection /jp-journals

Comparative Study of Transvaginal Sonography and Hysteroscopy for the Detection /jp-journals JSAFOG Comparative Study of Transvaginal Sonography and Hysteroscopy for the Detection 10.5005/jp-journals-10006-1580 of Endometrial Lesions in Women ORIGINAL ARTICLE Comparative Study of Transvaginal

More information

Abnormal Uterine Bleeding

Abnormal Uterine Bleeding Abnormal Uterine Bleeding Randy A. Fink, MD, FACOG Obstetrics & Gynecology A simplified approach for primary care Disclosures I have no relevant disclosures pertaining to this program. Learning Objectives

More information

Chawla Indu Tripathi Suchita Vohra Poonam Singh Pushpa

Chawla Indu Tripathi Suchita Vohra Poonam Singh Pushpa DOI 10.1007/s13224-013-0501-4 ORIGINAL ARTICLE To Evaluate the Accuracy of Saline Infusion Sonohysterography (SIS) for Evaluation of Uterine Cavity Abnormalities in Patients with Abnormal Uterine Bleeding

More information

Diagnostic accuracy of sonohysterography compared to endometrial biopsy in pre-menopausal women with abnormal uterine bleeding

Diagnostic accuracy of sonohysterography compared to endometrial biopsy in pre-menopausal women with abnormal uterine bleeding Original Article Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences Diagnostic accuracy of sonohysterography compared to endometrial biopsy in pre-menopausal women

More information

Article begins on next page

Article begins on next page Association of cervical microglandular hyperplasia with exogenous progestin exposure Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters.

More information

Abnormal Uterine Bleeding Case Studies

Abnormal Uterine Bleeding Case Studies Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead

More information

Disclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent

Disclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent 17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,

More information

Menorrhagia Update. Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland

Menorrhagia Update. Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland Menorrhagia Update Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland What is it? Subjective Excessive blood loss at time of menstruation flooding heavy clots Objective > 80mls volume

More information

MEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION

MEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003 HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College

More information

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:

Page # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases: Endometrium Pathology of the Endometrium Thomas C. Wright Columbia University, New York, NY Most common diseases: Abnormal uterine bleeding Inflammatory conditions Benign neoplasms Endometrial cancer Anatomical

More information

Columbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3

Columbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3 17β-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia Rogerio A Lobo, MD 1 ; David F Archer,

More information

IMPORTANT REMINDER DESCRIPTION

IMPORTANT REMINDER DESCRIPTION Medical Policy Manual Surgery, Policy No. 01 Endometrial Ablation Next Review: February 2019 Last Review: September 2018 Effective: October 1, 2018 IMPORTANT REMINDER Medical Policies are developed to

More information

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 550 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion 4.1.1 Humans The pharmacokinetics of the newer progestogens, desogestrel,

More information

Diagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding and Abortion

Diagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding and Abortion American Journal of Applied Sciences 9 (1): 13-17, 2012 ISSN 1546-9239 2012 Science Publications Diagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding

More information

Postmenopausal Asymptomatic. Endometrial Thickening: Patient. Characteristics and Pathology

Postmenopausal Asymptomatic. Endometrial Thickening: Patient. Characteristics and Pathology Research Article imedpub Journals www.imedpub.com Womens Health and Reproductive Medicine Abstract Postmenopausal Asymptomatic Endometrial Thickening: Patient Characteristics and Pathology Background:

More information

Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids

Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies

More information

Research. Breast cancer represents a major

Research. Breast cancer represents a major Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.

More information